» Articles » PMID: 30282317

Copper Radiopharmaceuticals for Theranostic Applications

Overview
Journal Eur J Med Chem
Specialty Chemistry
Date 2018 Oct 5
PMID 30282317
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The growing advancement in nuclear medicine challenges researchers from several different fields to integrate imaging and therapeutic modalities in a theranostic radiopharmaceutical, which can be defined as a molecular entity with readily replaceable radioisotope to provide easy switch between diagnostic and therapeutic applications for efficient and patient-friendly treatment of diseases. For such a reason, the diagnostic and therapeutic potential of all five medical radionuclides of copper have thoroughly been investigated as they boost the hope for development of successful radiotheranostics. To facilitate the mutual understanding between all different specialists working on this multidisciplinary field, we summarized the recent updates in copper-based nuclear medicine, with specific attention to the potential theranostic applications. Thereby, this review paper is focused on the current achievements in the copper-related complementary fields, such as synthetic and nuclear chemistry, biological assessment of radiopharmaceuticals, design and development of nanomaterials for multimodal theranostic implications. This work includes: i) description of available copper radionuclide production methods; ii) analyses of the synthetic strategies for development of improved copper radiopharmaceuticals; iii) summary of reported clinical data and recent preclinical studies from the last five years on biological applicability of copper radiopharmaceuticals; and iv) illustration of some sophisticated multimodal nanotheranostic agents that comprise several imaging and therapeutic modalities. Significant advancement can be seen in the synthetic procedures, which enables the broader implication of pretargeting approaches via bioorthogonal click reactions, as well as in the nanotechnology methods for biomimetic construction of biocompatible multimodal copper theranostics. All this gives the hope that personalized treatment of various diseases can be achieved by copper theranostics in the near future.

Citing Articles

Radiocopper in Radiopharmacy and Medical Use: Current Status and Perspective.

Krecisz P, Stefanska K, Studzinski J, Pitucha M, Czylkowska A, Szymanski P J Med Chem. 2025; 68(3):2356-2376.

PMID: 39895089 PMC: 11831595. DOI: 10.1021/acs.jmedchem.4c02885.


Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer.

Ismuha R, Ritawidya R, Daruwati I, Muchtaridi M Molecules. 2025; 29(24.

PMID: 39770150 PMC: 11679579. DOI: 10.3390/molecules29246062.


Enhancing the radionuclide theranostic concept through the radiohybrid approach.

Kronke T, Kopka K, Mamat C RSC Med Chem. 2024; .

PMID: 39618962 PMC: 11606402. DOI: 10.1039/d4md00591k.


Synthesis and Evaluation of [Cu]Cu-NOTA-HFn for PET Imaging of Transferrin Receptor 1 Expression in Nasopharyngeal Carcinoma.

Shen Y, Zhou R, Bi L, Huang G, Yang M, Li Z ACS Omega. 2024; 9(15):17423-17431.

PMID: 38645324 PMC: 11024937. DOI: 10.1021/acsomega.4c00187.


Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation.

Dhoundiyal S, Srivastava S, Kumar S, Singh G, Ashique S, Pal R Eur J Med Res. 2024; 29(1):26.

PMID: 38183131 PMC: 10768149. DOI: 10.1186/s40001-023-01627-0.